HPV screening tests to detect cervical pre-cancer and cancer
文件標題: 2024 WHO 子宮頸癌前病變及癌症檢測用人類乳突病毒篩檢測試之目標產品概況 (HPV screening tests to detect cervical pre-cancer and cancer) 來源: 世界衛生組織 (WHO), 2024. ISBN 978-92-4-010027-5 (electronic version) 目的: 本文件旨在概述 WHO 針對子宮頸癌前病變及癌症檢測用 HPV 篩檢測試所設定的目標產品概況 (TPP),以指導測試開發者和製造商,確保其產品符合公共衛生需求,特別是在資源有限的環境中,並協助實現全球消除子宮頸癌的目標。 主要主題: 子宮頸癌作為全球公共衛生問題: 子宮頸癌是全球女性中第四大常見癌症及第四大死因,特別在低收入和中等收入國家(LMICs)發病率和死亡率極高,主要原因歸咎於缺乏高質量的篩檢和有效的治療。 引文: "Among women globally, cervical cancer is the fourth most common cancer and the fourth leading cause of death, accounting for around 662 000 new cases and 349 000 deaths in 2022. It is the most commonly diagnosed cancer in women in 25 countries, many of which are in sub-Saharan Africa... Elevated mortality rates in LMICs are generally not attributable to elevated levels of infection with carcinogenic HPV (cHPV) types. Instead, they are mainly attributable to the lack of high-quality cervical cancer screening and efficient detection and treatment of pre-cancer lesions and management of invasiv...